Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Seconda… (NCT07064759) | Clinical Trial Compass
RecruitingPhase 3
Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration
United States, Argentina, Australia480 participantsStarted 2025-07-22
Plain-language summary
A Phase 3, Randomized, Double-Masked, Active-Controlled Trial in Adults with Macular Neovascularization Secondary to Age-Related Macular Degeneration
Who can participate
Age range
50 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
. Treatment naïve, i.e. no prior IVT anti-VEGF therapy OR
. Previously treated with no more than 4 IVT anti-VEGF injections due to nAMD and received diagnosis of nAMD no more than 6 months prior to the Screening Visit AND documented evidence of anatomical improvement and visual stability/improvement in response to previous IVT anti-VEGF treatment, as determined by the Investigator
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1This trial uses a single injection of 4D-150 and then measures vision at 52 weeks — how does that compare to the repeated injections I might need with standard anti-VEGF treatments, and is a one-time approach something you think is realistic based on what's known so far?
2Since this is a Phase 3 trial, what do you know about how 4D-150 performed in earlier phases, and does that safety and effectiveness data make you comfortable considering it as an option for my situation?
3The trial measures changes in ETDRS letter score over a year — based on where my vision is right now, is that the most important thing to be tracking for me, or are there other aspects of my macular degeneration you'd be more focused on?
4If I enrolled and the single injection didn't work well enough over the 52 weeks, what would my options be at that point — would I still be able to access standard anti-VEGF treatments, or could participation affect that?
5Given that this trial is actively recruiting right now, would you recommend I consider it before starting any standard treatment, or does it make more sense for me to try an established therapy first and keep this as a potential alternative?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Mean change from baseline in Best Corrected Visual Accuity (BCVA) Early Treatment for Diabetic Retinopathy (ETDRS) letter score at Week 52